指南与共识淋巴瘤浆细胞疾病

欧洲核医学协会(EANM)Focus 4 共识推荐:血液系统肿瘤的分子影像与治疗

European Association of Nuclear Medicine (EANM) Focus 4 consensus recommendations: molecular imaging and therapy in haematological tumours.
指南 / 共识 · Lancet Haematol · 2023-01-01

因高级别证据匮乏且对核医学用于血液系统恶性肿瘤存在意见分歧,EANM Focus 4 采用三阶段共识流程:系统评价现有证据质量、基于文献生成153条陈述(首轮后追加1条共154条)、由26名专家进行两轮电子德尔福投票(1-9分Likert量表),采用RAND/UCLA适宜性方法分析。所识别的系统评价均评为低至中等质量,两轮投票后154条陈述中139条(90%)达成共识,多数关于PET用于非霍奇金与霍奇金淋巴瘤的陈述达成共识,多发性骨髓瘤需更多研究确定治疗评估的最佳序列。

要点

  • 154条陈述中139条(90%)经两轮德尔福投票达成共识。
  • 多数关于PET用于非霍奇金和霍奇金淋巴瘤的陈述达成共识。
  • 多发性骨髓瘤需更多研究确定治疗评估的最佳序列。

核心结论

  • 专家小组就血液系统肿瘤分子影像与治疗相关陈述中的139/154条(90%)达成共识。
  • 多发性骨髓瘤领域需更多研究以确定治疗评估的最佳序列。
  • 核医学医师与血液科医师正等待一致文献以将体积参数、人工智能、机器学习和放射组学引入常规实践。

研究设计与样本

  • 欧洲核医学协会(EANM)Focus 4 共识流程,采用三阶段共识方法。
  • 第一阶段系统评价并评估现有证据质量,每个主题识别出1至14篇系统评价,均评为低至中等质量。
  • 第二阶段基于文献综述生成153条陈述,第一轮后追加1条,共154条。
  • 第三阶段由26名专家(从已发表血液系统肿瘤研究的作者中有目的抽样)进行两轮电子德尔福评审,采用1(强烈不同意)至9(强烈同意)Likert量表评分,使用RAND与加州大学洛杉矶分校适宜性方法分析。

主要发现

  • 两轮投票后,154条陈述中139条(90%)达成共识。
  • 关于PET用于非霍奇金淋巴瘤和霍奇金淋巴瘤的多数陈述达成共识。
  • 每个主题识别出1至14篇系统评价,所有系统评价均评为低至中等质量。

关键数值与推荐

  • 共识定义为专家小组就陈述达成一致,最终139/154条(90%)陈述达成共识。
  • 在多发骨髓瘤中,需更多研究确定治疗评估的最佳序列。
  • 将体积参数、人工智能、机器学习和放射组学引入常规实践尚需一致文献。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 现有证据中每个主题仅识别出1至14篇系统评价,且所有系统评价均评为低至中等质量。
  • 多发性骨髓瘤领域需更多研究以确定治疗评估的最佳序列。
  • 将体积参数、人工智能、机器学习和放射组学引入常规实践尚需一致文献。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Given the paucity of high-certainty evidence, and differences in opinion on the use of nuclear medicine for hematological malignancies, we embarked on a consensus process involving key experts in this area. We aimed to assess consensus within a panel of experts on issues related to patient eligibility, imaging techniques, staging and response assessment, follow-up, and treatment decision-making, and to provide interim guidance by our expert consensus. We used a three-stage consensus process. First, we systematically reviewed and appraised the quality of existing evidence. Second, we generated a list of 153 statements based on the literature review to be agreed or disagreed with, with an additional statement added after the first round. Third, the 154 statements were scored by a panel of 26 experts purposively sampled from authors of published research on haematological tumours on a 1 (strongly disagree) to 9 (strongly agree) Likert scale in a two-round electronic Delphi review. The RAND and University of California Los Angeles appropriateness method was used for analysis. Between one and 14 systematic reviews were identified on each topic. All were rated as low to moderate quality. After two rounds of voting, there was consensus on 139 (90%) of 154 of the statements. There was consensus on most statements concerning the use of PET in non-Hodgkin and Hodgkin lymphoma. In multiple myeloma, more studies are required to define the optimal sequence for treatment assessment. Furthermore, nuclear medicine physicians and haematologists are awaiting consistent literature to introduce volumetric parameters, artificial intelligence, machine learning, and radiomics into routine practice.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Nanni C, Kobe C, Baeßler B, et al. European Association of Nuclear Medicine (EANM) Focus 4 consensus recommendations: molecular imaging and therapy in haematological tumours. Lancet Haematol. 2023. PMID: 37142345. doi:10.1016/S2352-3026(23)00030-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。